Novartis execs on compliance: “Why be afraid of the truth?”

Novartis’s Shannon Thyme Klinger and Klaus Moosmayer talk to GIR about how the pharmaceutical company changed its approach to compliance in the midst of a series of government investigations.

Get unlimited access to all Global Investigations Review content